丹梔逍遙散對於慢性B型肝炎的治療效果及對拉美芙錠治療的助益

許金川 
國立台灣大
慢性B型肝炎導致的肝硬化、肝癌長久以來一直是國人健康的威脅。因此B型肝炎的治療極為重要。近年來慢性B型肝炎的治療已有長足的進步。B型肝炎以Lamivudine治療得到不錯的成績。中藥在這方面的應用也有不錯的結果，但很少有中藥加西藥的治療報告出現。

本研究的目的就是要研究中藥的丹梔逍遙散對於慢性B型的治療效果，以及它們是否能提高Lamivudine對於慢性B型肝炎的療效。

研究病人主要為肝鬱脾虛慢性B型肝炎，採開放式隨機對照性臨床試驗，120位病人。病人隨機分配於對照組（以安慰劑治療）以及三組實驗組。第一組實驗組以中醫辯證而給予丹梔逍遙散；第二組給予Lamivudine；第三組給予丹梔逍遙散加上Lamivudine。治療期為52週，並追蹤16週，以ALT值的降低、HBV DNA的降低、HBeAg/Anti-HBe的血清轉換，以及HBV聚合部分YMDD的突變比率為評估依據。

關鍵字：慢性B型肝炎、肝鬱脾虛、丹梔逍遙散、拉美芙錠

Therapeutic effects of Kami-Shoyo-San on chronic hepatitis B: used alone or in combination with Lamivudine

Jin-Chuan Sheu
Department of Internal Medicine , College of Medicine National Taiwan University
Liver cirrhosis and hepatocellular carcinoma resulted from chronic hepatitis B viral infection has long been a major issue in the health program in Taiwan. Thus, successful therapies toward chronic hepatitis B is very important here. Recently, clinical results has shown great promise in this treatment. Lamivudine has gained a lot of enthusiasm because of its efficacy with less side effects than interferons. On the other hand, treatment by herbal medicine has also played some role, but there were no report on the combination therapy with Lamivudine plus herbal medicine.

The aims of this study are to investigate the theuapeutic effects of Kami-Shoyo-San on the patients with chronic hepatitis B and also to investigate how Kami-Shoyo-San will affect the efficacy of Lamivudine.

One hundred and twenty patients with chronic hepatitis B will be enrolled and openly assigned into 4 groups：1)placebo, 2)Kami-Shoyo-San alone, 3)Lamivudine alone, 4)Kami-Shoyo-San plus Lamivudine. They will be
關鍵字：Chronic hepatitis B, Gan-Yu-Pi-Hsu, Kami-Shoyo-San, Lamivudine